Cytokinetics Executive VP Sells 15,000 Shares at $60.28, Trims Holdings
Executive VP Andrew Callos sold 15,000 Cytokinetics shares at $60.28 on January 5, reducing his holdings to 50,440 after prior December sales of 53,528 shares at about $65.95, per SEC filings. The stock’s 52-week range spans $29.31 to $70.98, with a market cap of approximately $7.29 billion and daily volume near 2.25 million shares.
1. Significant Insider Share Sales by Executive Vice President
On January 5, 2026, Cytokinetics Executive Vice President Andrew Callos sold 15,000 shares of company stock, reducing his total holdings to 50,440 shares. This transaction follows two substantial sales in December—1,042 shares on December 8 and 52,486 shares on December 5—bringing his aggregate proceeds from those December sales to approximately $3.46 million. All trades were reported in SEC filings within the required two-business-day window, providing investors with transparent insight into insider liquidity activity at the firm.
2. Upcoming Presentation at J.P. Morgan Healthcare Conference
Cytokinetics President and Chief Executive Officer Robert I. Blum is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 at 9:45 AM Pacific Time. The live webcast will be accessible via the Investors & Media section of the company’s website, with an on-demand replay archived for 90 days. Investors will look for updates on MYQORZO (aficamten), approved in the U.S. and China for symptomatic obstructive hypertrophic cardiomyopathy, as well as progress on omecamtiv mecarbil for heart failure with reduced ejection fraction and ulacamten for preserved ejection fraction, plus developments in preclinical muscle biology research.